A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group ：OGSG1203 (HERBIS-5)　

A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group ：OGSG1203 (HERBIS-5)

Multicenter phase II trial of adjuvant S-1 plus Docetaxel for 6 months in patients with pathological stage III gastric cancer (OGSG1002)

A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: OGSG1203 (HERBIS-5)

Effects of an oral elemental nutrition supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: a phase II study (OGSG1108)

A phase II study to examine the effectiveness of nutritional support with elemental diet for stage II/III gastric cancer patients receiving adjuvant chemotherapy with S-1 (OGSG 1108)

Phase II study of S-1 plus docetaxel as first-line treatment for elderly patients with advanced gastric cancer (OGSG0902)

Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with triweekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC) (HERBIS-4A / OGSG 1105)

Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3)

A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (HERBIS-4B / OGSG 1106)